Neurotoxicity induced by soluble amyloid oligomers is associated with glutamatergic hyperexcitation and the pro-inflammatory mediator .
can both promote and restrain neurotoxicity caused by soluble amyloid oligomers.
Inducing protective microglial signaling reduced neurotoxicity linked to amyloid exposure.
Depleting microglia worsened neurotoxicity from amyloid and TRAIL.
Repopulated microglia exhibited resistance to amyloid-induced neurotoxicity.
Proteomic analysis indicated that repopulated microglia have an anti-inflammatory phenotype, contrasting with amyloid-exposed microglia.
mTORC2 and IRF7 were identified as potential drug targets for intervention.
Simplified
BACKGROUND: Alzheimer's disease (AD) features progressive neurodegeneration and microglial activation that results in dementia and cognitive decline. The release of soluble amyloid (Aβ) oligomers into the extracellular space is an early feature of AD pathology. This can promote excitotoxicity and microglial activation. can adopt several activation states with various functional outcomes. Protective microglial activation states have been identified in response to Aβ plaque pathology in vivo. However, the role of microglia and immune mediators in neurotoxicity induced by soluble Aβ oligomers is unclear. Further, there remains a need to identify druggable molecular targets that promote protective microglial states to slow or prevent the progression of AD.
METHODS: Hippocampal entorhinal brain slice culture (HEBSC) was employed to study mechanisms of Aβoligomer-induced neurotoxicity as well as the role of microglia. The roles of glutamate hyperexcitation and immune signaling in Aβ-induced neurotoxicity were assessed using MK801 and neutralizing antibodies to the TNF-related apoptosis-inducing ligand () respectively. Microglial activation state was manipulated using Gi-hM4di designer receptor exclusively activated by designer drugs (DREADDs), microglial depletion with the colony-stimulating factor 1 receptor (CSF1R) antagonist PLX3397, and microglial repopulation (PLX3397 withdrawal). Proteomic changes were assessed by LC-MS/MS in microglia isolated from control, repopulated, or Aβ-treated HEBSCs. 1-42
RESULTS: Neurotoxicity induced by soluble Aβoligomers involves glutamatergic hyperexcitation caused by the proinflammatory mediator and death receptor ligand TRAIL. Microglia were found to have the ability to both promote and restrain Aβ-induced toxicity. Induction of microglial Gi-signaling with hM4di to prevent pro-inflammatory activation blunted Aβ neurotoxicity, while microglial depletion with CSF1R antagonism worsened neurotoxicity caused by Aβ as well as TRAIL. HEBSCs with repopulated microglia, however, showed a near complete resistance to Aβ-induced neurotoxicity. Comparison of microglial proteomes revealed that repopulated microglia have a baseline anti-inflammatory and trophic phenotype with a predicted pathway activation that is nearly opposite that of Aβ-exposed microglia. mTORC2 and IRF7 were identified as potential targets for intervention. 1-42
CONCLUSION: Microglia are key mediators of both protection and neurodegeneration in response to Aβ. Polarizing microglia toward a protective state could be used as a preventative strategy against Aβ-induced neurotoxicity.
Key numbers
54%
Decrease in Aβ-induced neurotoxicity
activation in leads to reduced excitotoxicity.
20%
Increase in neuronal injury from microglial depletion